BioSpace News Archive

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the publication of its first in human Phase I clinical trial with its novel monoclonal antibody, NEO-201, targeting the truncated core-1 O-glycan.

Xilio Therapeutics, Inc. announced that the Compensation Committee of the Board of Directors granted a non-qualified stock option to purchase 55,000 shares of common stock to Kevin Brennan, the company’s newly hired Senior Vice President, Finance and Accounting.

Supernus Pharmaceuticals, Inc. announced that it has paid the total principal amount due of $402.5 million under its 0.625% Convertible Senior Notes due 2023, in addition to payment of the remaining outstanding interest due of $1.3 million.

TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2’s common stock to two non-executive new hires.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.

PHC Corporation and NovaScan, Inc. announce the launch of a collaboration through which they will seek to explore the feasibility of MarginScanTM, an investigational “ex vivo” medical device that will seek to support physicians in detecting non-melanoma skin cancers.

iNtRON Biotechnology has announced that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

BioArctic AB announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta protofibril[1] antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using a disease simulation model in the peer-reviewed journal Neurology and Therapy.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Over-the-Counter hearing aid space, announced its unaudited financial results for the full year ended December 31, 2022.

Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrating that CampbellCell universal donor stem cells reduce symptoms of schizophrenia in an animal model through stimulation of immune modulation and production of the cytokine brain derived neurotrophic factors (BDNF).